SCHEMBL6223677

SCHEMBL6223677

CC(C)[C@H]1CC[C@H](Nc2ncc(CCc3cccnc3)c3ccccc23)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 1/20 0.43
▸ GBA1 P04062 8/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE7A Q13946 1/20 0.39
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ FLT3 P36888 1/20 0.35
▸ TYRO3 Q06418 1/20 0.35
▸ MERTK Q12866 1/20 0.35
▸ GAS6 Q14393 1/20 0.35
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6223756 1.00 GRM4 (0.43) GRM4GBA1PDE4BPDE7ALMNA
SCHEMBL1383329 1.00 GRM4 (0.43) GRM4GBA1PDE4BPDE7ALMNA
SCHEMBL1382994 0.88 GRM4 (0.40) GRM4GBA1LMNAIRAK4
SCHEMBL1386115 0.86 GBA1 (0.53) GBA1PDE4BPDE7ALMNAPOLB
SCHEMBL6223769 0.86 GBA1 (0.53) GBA1PDE4BPDE7ALMNAPOLB
SCHEMBL6223107 0.86 GBA1 (0.53) GBA1PDE4BPDE7ALMNAPOLB
SCHEMBL6223355 0.85 ALDH1A1 (0.41) GBA1PDE4BPDE7ALMNAPOLB
SCHEMBL1383369 0.85 ALDH1A1 (0.41) GBA1PDE4BPDE7ALMNAPOLB
SCHEMBL6219896 0.85 ALDH1A1 (0.41) GBA1PDE4BPDE7ALMNAPOLB
SCHEMBL4825401 0.83 GRM4 (0.39) GRM4CYP1A2CYP2D6TYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254138-B1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2005-05-11 — — EP claimed
EP-1603566-B1 USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES NOVARTIS AG (CH) 2009-01-21 — — EP disclosed
Send feedback